What are the outcomes of long-lasting commitment between universities and pharmaceutical companies?

What are the outcomes of long-lasting commitment between universities and pharmaceutical companies?

To which needs do these numerous collaboration schemes answer? What are the specificities of these agreements in terms of management models and R&D means mutualisation. Are short-term reports and industry constraints coherent with multi-years academic agreements?

Ulrik Rahbek

Vice President
Denmark
Novo Nordisk

Isabelle Barlat

Strategy&Business Development-R&D Transaction Manager
France
SANOFI

Christopher Keely

Senior Business Development Manager
Ireland
TRINITY COLLEGE DUBLIN
  • No products in the cart.